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Lead Toxicity: From Overt to Subclinical
to Subtle Health Effects
by Robert A. Goyer*
Although the toxicity of lead was recognized centuries ago, concern was restricted to overt symptoms:
colic, encephalopathy, anemia, or renal disease. Two major reasons for lack of progress in restricting
toxicity were that interest was limited to occupational exposures and there was a lack of awareness of
specific biochemical ormetaboliceffects. Identification ofsubclinical effectshasbeenpossiblethelast15or
20 years because ofthe development ofsensitive measures to detect cognitive and behavioral changes that
are not apparent clinically and because ofmethods to measure the reduced activity ofheme enzymes. This
progress was driven by basic and clinical research that resulted in a better understanding of cellular
toxicology. Thenewawarenesspromptedtheloweringofacceptableoccupationalexposures, asmeasuredby
blood lead from 80 to 40 to 60 1Rg/dL range, and the establishment ofmaximum recommended exposures in
children to ablood lead level of25 ,ug/dL. Loweringthe lead content ingasoline has been accomplished by a
nearly 50%o decrease in average blood levels of persons in the United States (NHANES II data). Current
research implicates lead as a contributing etiologic factor in a number ofcommon diseases affecting large
portions of the population such as subtle cognitive and neurological deficits, hypertension, congenital
malformations, immunotoxicity, anddeficits in growth anddevelopment. Foreach ofthese disorders there
may be multiple etiologic factors; the scientific challenge is to develop sensitive methodology to detect the
specific role oflead. Otherpotential subtle health effects include the influence ofsmall amounts oflead on
cell proliferation and lead as a cofactor in carcinogenesis. At the molecular level, lead may be competing
with calcium to alter critical cell functions such as ion transport, energy production, and the function of
heme-containing enzymes. The public health need for the next century will be to provide an environment
that will reduce human exposure to lead to a level consistent with optimal human health. Although
considerable success hasbeen achievedthroughreduction ofairemissions, decreases in lead levelsfound in
food and water must occur in the face ofincreasing solubilization and mobilization ofthis metal by other
environmental influences such as the acid rain phenomenon.
Introduction
The objective of this brief paper is to provide an
overview ofhuman health effects oflead, bringing par-
ticular attention to the gradual reduction ofacceptable
levels oflead exposure, since the clinical recognition of
lead toxicity has progressed from overt to subelinical to
subtle effects. The history of lead usage and health
effectsgoesbackmorethan20centuries, witharemark-
ably repetitive record of lead poisoning occurring well
intothiscentury. Itisdifficulttocompletelyanswerwhy
so little progress has been made in controlling lead
toxicity in previous years, which was not for lack of
awareness because lead toxicity was frequently written
about. One reason forthe lack ofchange often cited was
thatthefocushistoricallywasonoccupationaltoxicity-
on the worker rather than the general population.
Another reason may be the nature ofclinical lead toxic-
ity. It is an insidious problem; affected people had to
develop overt illness, a severe anemia, or a neuropathy
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or encephalopathy before being recognized as being ill.
But all ofthis has changed in the past 15 to 20 years.
Wenowrealizethat overt and subclinicaltoxicityform a
continuum and the difference depends on the eyes one
uses to see an effect, whether or not itis achild with an
ataxic gait or a child whose nervous system function is
measured by sensitive neurophysiologic probes. Both
approaches measure toxicity; the difference in terms of
health effect is only one of degree. However, to define
and measure subclinical effects, we have had to under-
stand pathogenetic mechanisms and developmethods to
measurethem; thishasonlybeenpossiblebecause ofthe
continuing interests ofalarge number ofscientists from
a variety of clinical and basic disciplines. As a result
there has been a progressive decrease in acceptable
levels ofexposure, both inthe workplace and amongthe
general public particularly young children. This work
has not really been completed, so the present phase can
best be described as the treatment or corrective phase.
The level oflead reduction that is actually achievable
in the future is uncertain. Some have argued that the
natural human exposure to lead is negligible (1). Cer-
tainly, at the present time, lead is ubiquitous in theR. A. GOYER
environment. The metalis neither created ordestroyed
by man, but industrial activity results in redistributing
andsometimestransformingthemetaltochemicalforms
that are more available and more toxic to man.
Lead is and will continue to be an important metal
with many industrial uses, the principle one being the
electric battery industry. However, leaded gasoline
combustioninvehicleshasaccountedfor asmuch as90%
of the total anthropogenic sources of environmental
lead. From 1975 to 1984 lead in gasoline decreased 73%,
while ambient air lead decreased 71% (2). However, all
human exposure to lead is not from the inhalation of
airbornelead. Foraboutfourdecades nowmorethan 100
to 200,000 tons oflead per year have been emitted from
automobile exhausts in the United States with some
fixation to soil, uptake by plants, and flow into water
sources. Presentlythemajor sourcesofhuman exposure
toleadby persons inthegeneralpopulation arefoodand
beverage because oflead uptake by food sources and its
presence in drinking water. Solubilization and mobil-
ization of lead is enhanced by a lower pH of water, so
there must be some concern for the effects of the acid
rain phenomenon and its contribution to human lead
exposure (3). This exposure maybe aninstance whereit
is reduced by one corrective measure, the phase-out of
lead in gasoline, only to have human exposure further
enhanced by a second environmental problem, the acid
rain phenomenon.
Discussion
So what is the challenge for the next century? The
majorscientific question will be to determine the lowest
level oflead exposure thatistoxic. There have beenreal
advances in understanding the toxicology of lead over
the past 15 to 20 years. Table 1 summarizes the levels of
blood lead thought to be associated with different kinds
of effects. The first three effects are signs of overt
toxicity, which are easily recognized but not thought to
occur until blood lead levels reached 80 ,ug/dL or more
[the occupational health standard priorto 1978 (4)]. The
recognition that subclinical but nonetheless harmful ef-
fects occuratlower blood lead levelsbeganinthe 1970s.
Because the scientific understanding oflead effects and
increasingly sensitive techniques for measuring them
have evolved, the recognizable toxicological effect of
leadhasbeenfound to occuratmuchlowerlevels. These
findings have driventhe need to restrict exposure, both
in the workplace and ambient environment, to lower
levels. The 1985reportfromCentersforDiseaseControl
(CDC) recommended that 25 ,g/dL of blood lead be
considered as the action level in children. However,
there is a growing body of information that this level
may be too high, particularlyforthe fetus (5). Although
this figure illustrates the progress that has taken place,
there is now a need to address the problem of subtle
effects. These are effects that differfromclinical effects
and can only be recognized by very sensitive epidemi-
ological studies or by laboratory techniques. In general
these are not lead-specific effects; they are common in
the general population and they are multifactorial, that
is, lead is only one of a number of possible etiological
factors.
Cognitive and behavioral effects are perhaps the
single most important subtle ones. These are discussed
in detail later in this conference (6). An effect oflead on
blood pressure was suggested more than 100 years ago
(7), but until recently both epidemiological and experi-
mental results were inconsistent, probably because of
methodological differences and problems. A number of
studiesinvolvingleadworkers and people inthegeneral
population have shown a more consistent relationship
between lead exposure and the increase in blood pres-
sure or hypertension (8,9). Analyses of NHANES II
data(10) fromwhitemales, ages40to59 years, showed a
significant association between blood lead and blood
pressure, even after including-in multiple regression
analyses-all known factors previously established as
being correlated with blood pressure. No threshold was
found where the blood lead level was not significantly
related toblood pressure across a range of7to 34 ,ug/dL
of blood lead. An interesting aspect of these studies is
that large initial increments in blood pressure occurred
at relatively low blood lead levels, followed by blood
pressure increments leveling off at higher blood lead
levels. A growing amount of experimental work pro-
videsmechanisticexplanationsforthiseffectoflead, and
both the epidemiological and experimental studies to
Table 1. Blood lead levels (,ug/dL) associated with different toxicological effects of lead and no-effect levels recognized by different
government agencies.
Effect Adults Children No effect
Gastrointestinal colic > 80 > 80 60-70 Adults (WHO, 1977)'
Acute encephalopathy > 80 > 80 50-60 Children (WHO, 1977)
Anemia > 80 > 70 40-60 (OSHA, 1978)a
Chronic renal disease > 60 30 (CDC, 1978)a
Cognitive and behavioral > 30 > 15
Peripheral neuropathy > 30 > 20
Reproductive testicular > 40
Increase EP > 20-25 > 15
ALA-D > 20 > 10
Pyridine-5-nucleosidase > 10
Subtle effects, tolerable level? 25 (CDC, 1985)
aWHO, World Health Organization; OSHA, Occupational Safety and Health Administration; CDC, Centers for Disease Control.
178LEAD TOXICITY
date were reviewed in a 1988 symposium (11).
An epidemiologic study reported by Needleman and
co-workers (12) suggests a relationship between cord
blood lead levels from 8.7 to >35 g/dL and a number of
minor congenital malformations such as hemangiomas,
minor skin anomalies, and undescended testes. How-
ever, these findings were not confirmed in two other
studies (13,14).
In the late 1970s at least three epidemiologic studies
relating blood lead levels to skeletal growth and stature
suggested an adverse effect (15,16), but it has not been
possible to separate lead effects fromthe contribution of
dietary, racial, and other factors.
Schwartz et al. (17) analyzed anthropometric mea-
surements with age, sex, and other variables and found
that height, weight, and chest circumference were ex-
plained by five variables: sex, age, race, diet (that is
calories or protein), and blood lead levels.
This association between lead exposure and growth is
supported by animal studies and seems to have further
support from ongoingprospective studies. However, at
present there is no dose-response information and the
mechanistic basis is largely speculative.
An important point to realize in relating these effects
to lead is that in all three ofthese end points, the lead
effect is only one of a large number of possible con-
tributing factors. Probably the lead effect is never the
only factor, so it may be recognized in population stud-
ies, but it is unlikely that the lead effect is accurately
weighted in a particular individual.
In discussing subtle effects it is also appropriate to
mention cellular or molecular effects that are measured
only in cells ofexperimental animals or in vitro models.
Figure 1 is a photomicrograph showing the ultra-
structure ofa kidney cell from a lead-poisoned rat. The
same changes are seen in kidney biopsies of lead-
exposed workmen. This is a sick cell; it is active and
functioning but at a reduced level. The cell shows two
major cellular effects of lead, the lead-induced nuclear
inclusion body and ultrastructural changes in the
mitochondria.
The lead-induced inclusionbodyisalead-protein com-
plex(18). Itprobablyformsinitiallyinthecytoplasmand
migrates into the nucleus (19). The protein has been
partially characterized (20,21), but its origin has not
been determined. This proteinmigration may indeed be
avery subtle effect oflead. Leadisbound to solubleand
insoluble nuclear protein fractions with exposure from
lead in the ambient environment (20). Lead does induce
protein synthesis (22,23), and inhibitors ofprotein syn-
thesis have impaired the formation oflead-protein com-
plexes in cells intissue culture (19), butthe origin ofthe
lead that forms the complex is not known. A positive
view of this phenomenon is that it sequesters cellular
lead from other organelles into a relatively harmless
form(24), buttheremaybesubtleeffectsofnuclearlead
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FIGURE 1. Electron photomicrograph ofproximal renal tubule of rat with lead toxicity. Nucleus contains dense, intranuclear inclusion body
adjacent to nucleolus. Mitochondria are swollen with distorted cristae.
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on the regulation of cell growth.
Whether or not lead is a carcinogen is not completely
resolved at present, according to the International
Agency for Research on Cancer (IARC) (25). A single
injection of lead stimulates [3H]-thymidine in renal tu-
bular cells, which is not believed to be due to repair
synthesis of DNA, because lead-stimulated DNA syn-
thesis is followed by a wave of mitoses in tubular epi-
thelium that does not occur after repair synthesis of
DNA. Lead induces liver cell proliferation (26), but
lead-induced liver cell hyperplasia does not support ini-
tiation by liver carcinogens (27). Lead does induce in
vitro transformation ofSyrian hamster embryo cell cul-
tures (28),which implies that lead does in some way
affectgeneexpression. Siroverand Loeb (29) foundthat
lead salts decrease fidelity of DNA transcription, but
lead is not mutagenic in the Salmonella (Ames test)
assay for point mutations (30) or in the host-mediated
assay in mice (31).
Lead does induce renal tumors in male rats and other
rodents but not in all species ofanimals. Epidemiologic
studies of lead smelter workers and battery workers
have demonstrated a significant excess ofmalignancies
at all sites and the lungs but not specifically the kidneys
(32).
The lead effect on functions ofthe mitochondrion site
may be the major site for the subtle biochemical effects
of lead. Lead was shown to reduce oxidative phos-
phorylation in kidney mitochondria about 20 years ago
and itbroughtattentiontothemitochondrion asperhaps
the most sensitive organelle or intracellular focus for
lead toxicity (33). Impaired energy metabolism results
in reduction ofthe normal function ofthe cellregardless
ofthe organ system. Lead has been shown to affect the
functionofmitochondriaineveryorganthatreflectslead
toxicity clinically: the brain, the kidney, and the hema-
topoietic system in particular. There is also impairment
ofotherfunctionsofthemitochondrionincludingsodium
and potassium ATPases, and Ca ATPases that lead to
impaired cation regulation, particularly with regard to
calcium (34). Calcium serves as an important intra-
cellular messenger, and small changes in the calcium
concentration bringaboutlarge changes in cell response
so that regulation ofcalcium fluxes across plasma mem-
brane are critical to proper cell function (35). For in-
stance, calciumserves as amessengerinbothneuraland
endocrine cells, so small amounts oflead in neural cells
maybringaboutchanges inneuronalfunction(36). Also,
calcium serves as an important intracellular messenger
in the regulation ofcardiac and smooth muscle function
andmayrelatetothepathogenesis ofhypertension (37).
Effects oncalciumhomeostasis insmoothmuscle cells in
arterioles may be the basis for the role of lead in
hypertension.
Lead has been found to have multiple effects on heme
metabolism, producing several different clinical effects
(38). Themajoreffect is onerythropoiesis, butthere are
also subtle effects on heme-containing enzyme systems,
such as cytochrome P-450 systems, and decreased vita-
min D metabolism. This metabolism requires a heme-
containing hydroxylase in the kidney for the hydrox-
ylation of 25-hydroxyvitamin D to 1,25-dehydroxy-
vitamin D, which is important in stimulating
gastrointestinal absorption of calcium (39).
Finally, there are polymorphisms of the heme-
synthesizingenzyme, ALA-D, whichmayhave different
degrees of sensitivity to lead and may be related to
differences in susceptibility to a particular level oflead
exposure. Whether or not there are different groups of
people in the general population that have different
susceptibilities tolead hasbeenaperplexingproblem. It
has long been recognized that in the workplace several
men may be doing the same job, working in the same
environment, and only a small number actually develop
symptoms oftoxicity. The same is true in epidemiology
studies of children: siblings in one family are affected
whereas those next door are not affected. Various ex-
planations have been offered for these differences such
as diet, particularly the content ofcalcium and iron, and
personal hygiene; for children these differences have
been termed the mother effect that includes many
things. Recently there has been some evidence suggest-
ing that genetic polymorphisms of aminolevulinic acid
dehydratase might account for some ofthe difference in
the susceptibility between two people. Rogan and co-
workers (40) noted that children with a more-than-
average increase in erythrocyte protoporphyrin for a
particular level ofblood lead have a more-than-average
decreaseind-aminolevulinic aciddehydratase (ALA-D),
suggesting differences inresponsiveness ofthis enzyme
in different people. The difference in these enzymes has
not yet been demonstrated in people having lead toxic-
ity, but we now knowthat at least two different genetic
forms of this enzyme are present in the general popu-
lation (41).
Asthereadercansee, themitochondrionisthe sitefor
several subtle and not-so-subtle effects oflead. A more
complete understanding ofthe relationship of these ef-
fects to measurable health effects should provide a bet-
ter basis for deciding what is the minimal toxic effect of
lead.
Summary
Research over the past 15 to 20 years has resulted in
methods of detection of subclinical effects of lead re-
sulting in some lowering of human exposure. Many
effects at the molecular level are also recognized but
withoutknowledge ofhumandose-response. Challenges
fornext century arefortoxicologist andepidemiologists
to determine the minimum lead health effect and for
environmentalists to provide an environment assuring
minimal human exposure.
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